Bing

SEARCH HISTORY

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Myriad Genetics ( MYGN) as a ...
The Street · 7/15/2014
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “buy” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Thursday. They currently have a $43.00 price target on the stock. Cantor Fitzgerald’s price objective ...
Ticker Report · 5/7/2015
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for genetic ...
Investors Business Daily · ByAmy Reeves · 3/12/2014
More from Bing News
Mannkind Corp (MNKD)- The company’s shares rose 6.3 pct Myriad Genetics (MYGN)- The company’s stocks rallied 5.1 ... Cantel Medical (CMN)- CMN stock is up 2.8 pct. Qiagen N.V. (QGEN)- QGEN stock is up 2.8 pct. Bluebird Bio Inc (BLUE)- The …
Fx Pips · 6/4/2015
Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of December 31, 2014, the Company has repurchased almost $1 billion …
StreetInsider · 2/24/2015
11/06/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Myriad Genetics Inc. MYGN, -1.28% NPS Pharmaceuticals, Inc. NPSP Durata Therapeutics, Inc. DRTX and Albany Molecular Research Inc. AMRI, +1.57% Myriad …
Market Watch · 11/7/2013
Myriad Genetics (MYGN) shares were up more than 11% yesterday to close at a 52-week high of $35.03 yesterday, after the company published data in the Journal of Urology proving that its recurring prostate cancer detection test, Prolaris, yielded positive ...
bidnessetc.com · 2/19/2014
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded down 0.77% on Thursday, hitting $33.41. 108,193 shares of the company’s stock traded hands. Myriad Genetics, Inc. has a 1-year low of $31.56 and a 1-year high of $40.50. The stock’s 50-day …
wkrb13.com · 5/7/2015
For gene-based cancer test maker Myriad Genetics, the high-court ruling that human DNA cannot be patented is killing the stock. Myriad Genetics (MYGN) stock at $27.59 lost more than 13% of its value just Friday, following Thursday’s U. S. Supreme …
Barron's · ByDimitra Defotis · 6/14/2013
(NYSE:SNE) – Sony Corp – Big prints in Sony Corp. call and put options this morning pushed the consumer electronics maker onto our ‘hot by options volume’ market scanner in the early going on Monday, with overall volume up above 21,000 …
Wall Street Pit · 5/13/2013